Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 01, 2017 14:43 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas to Present at the 37th Annual Cowen Health Care Conference

EMERYVILLE, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, is...
February 28, 2017 16:05 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2016

EMERYVILLE, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the fourth quarter and full-year...
February 28, 2017 08:30 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Presents Additional Open-Label, Long-Term Safety and Efficacy Data on ADS-5102 at the First Pan American Parkinson’s Disease and Movement Disorders Congress

EMERYVILLE, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the presentation of additional data from EASE LID 2, its Phase 3 open-label,...
February 17, 2017 08:00 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas to Present New ADS-5102 Data from Phase 2 Trial in Walking Impairment Associated with Multiple Sclerosis at ACTRIMS Forum 2017

EMERYVILLE, Calif., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) will present results from its Phase 2 proof-of-concept study of ADS-5102 (amantadine hydrochloride)...
January 08, 2017 19:57 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Outlines Key 2017 Priorities and Highlights 2016 Achievements

EMERYVILLE, Calif., Jan. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today outlines key business priorities for 2017, in addition to providing a review of 2016...
January 06, 2017 09:00 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease

-- PDUFA Action Date Set for August 24, 2017 -- -- If Approved, ADS-5102 will be the First and Only Medicine Approved for the Treatment of LID in Parkinson’s Disease -- EMERYVILLE, Calif.,...
January 03, 2017 16:52 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy

EMERYVILLE, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the completion of a Phase 1 clinical trial of ADS-4101, an investigational drug in...
November 15, 2016 16:05 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference

EMERYVILLE, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of...
November 03, 2016 16:05 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Reports Third Quarter 2016 Financial Results

EMERYVILLE, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced financial results for the quarter ended September 30, 2016. “This was a...
November 01, 2016 16:05 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals to Present at the Stifel 2016 Healthcare Conference

EMERYVILLE, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of...